We are live on ! Find out more
RAPT

RAPT Therapeutics

Delisted

RAPT was delisted on the 2nd of March, 2026.

54 hedge funds and large institutions have $443M invested in RAPT Therapeutics in 2020 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 24 increasing their positions, 4 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 4

400% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 4

77% more capital invested

Capital invested by funds: $250M → $443M (+$192M)

50% more funds holding in top 10

Funds holding in top 10: 23 (+1)

42% more funds holding

Funds holding: 3854 (+16)

1.65% more ownership

Funds ownership: 6.06%7.71% (+1.6%)

Holders
54
Holders Change
+16
Holders Change %
+42.11%
% of All Funds
1.11%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.06%
New
20
Increased
24
Reduced
4
Closed
4
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
TRSOTSOK
26
Teachers Retirement System of the State of Kentucky
Kentucky
$720K
California Public Employees Retirement System
27
California Public Employees Retirement System
California
$705K +$469K +3,035 New
Bank of America
28
Bank of America
North Carolina
$663K +$431K +2,787 +3,871%
California State Teachers Retirement System (CalSTRS)
29
California State Teachers Retirement System (CalSTRS)
California
$480K +$273K +1,768 +589%
VEA
30
Virtus ETF Advisers
New York
$472K +$315K +2,034 New
UBS Group
31
UBS Group
Switzerland
$451K +$270K +1,747 +878%
SCM
32
Soleus Capital Management
Connecticut
$438K +$292K +1,888 New
SCM
33
Sio Capital Management
New York
$415K
AllianceBernstein
34
AllianceBernstein
Tennessee
$383K +$255K +1,650 New
RhumbLine Advisers
35
RhumbLine Advisers
Massachusetts
$345K +$230K +1,486 New
New York State Common Retirement Fund
36
New York State Common Retirement Fund
New York
$293K +$170K +1,100 +675%
AL
37
Aspiriant LLC
California
$290K
Jane Street
38
Jane Street
New York
$285K +$190K +1,231 New
Morgan Stanley
39
Morgan Stanley
New York
$229K +$149K +963 +3,567%
AIG
40
American International Group
New York
$195K +$109K +707 +536%
SG Americas Securities
41
SG Americas Securities
New York
$172K +$115K +742 New
Deutsche Bank
42
Deutsche Bank
Germany
$162K +$98K +634 +1,039%
MIM
43
MetLife Investment Management
New Jersey
$155K +$103K +668 New
PA
44
Parallel Advisors
California
$129K +$86.4K +559 New
MLICM
45
Metropolitan Life Insurance Company (MetLife)
New York
$107K +$71.3K +461 New
FMT
46
First Mercantile Trust
Tennessee
$93K +$62.2K +402 New
Legal & General Group
47
Legal & General Group
United Kingdom
$52K +$29.8K +193 +585%
Citigroup
48
Citigroup
New York
$43K +$20.7K +134 +258%
AIP
49
Ameritas Investment Partners
Nebraska
$28K +$16.1K +104 +612%
TRCT
50
Tower Research Capital (TRC)
New York
$28K +$18.7K +121 New

RAPT Hedge Fund Activity: Q2 2020 in Review

54 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in RAPT Therapeutics (RAPT) for Q2 2020, worth a combined $443M — up 77% from $250M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new RAPT positions and 4 closed out — a net gain of 16 holders — while 24 added to existing stakes and 4 trimmed.

The largest buyer was Regents of the University of California, opening a new position worth an estimated $30.4M. The largest seller was Luminus Management, exiting entirely with an estimated $5.68M sold.

  • 54 institutional investors held RAPT Therapeutics (RAPT) as of Q2 2020, up from 38 in Q1 2020.
  • Funds reported $443M of RAPT Therapeutics stock for Q2 2020, up 77% quarter-over-quarter.
  • 20 funds opened new RAPT Therapeutics positions in Q2 2020 and 4 closed out, a net change of +16 holders.
  • The largest RAPT Therapeutics buyer in Q2 2020 was Regents of the University of California, an estimated $30.4M added.
  • The largest RAPT Therapeutics seller in Q2 2020 was Luminus Management, an estimated $5.68M sold.

Based on aggregated 13F filings for Q2 2020.